Business Description
Clene Inc
NAICS : 311999
SIC : 2834
Share Class Description:
CLNNW: Warrants (30/12/2025)Total Employee Number:
79Compare
Compare
Traded in other countries / regions
CLNN.USA84C0.Germany IPO Date
2020-12-31Description
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.43 | |||||
Equity-to-Asset | -1.08 | |||||
Debt-to-Equity | -0.9 | |||||
Debt-to-EBITDA | -0.64 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -24.17 | |||||
Beneish M-Score | -3.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -48.3 | |||||
3-Year EBITDA Growth Rate | 34.3 | |||||
3-Year EPS without NRI Growth Rate | 44.4 | |||||
3-Year FCF Growth Rate | 48.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1154.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.07 | |||||
Quick Ratio | 3.07 | |||||
Cash Ratio | 1.99 | |||||
Days Inventory | 331.59 | |||||
Days Sales Outstanding | 2817.17 | |||||
Days Payable | 6854.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -42.6 | |||||
Shareholder Yield % | -38.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.05 | |||||
Operating Margin % | -9884.77 | |||||
Net Margin % | -20059.9 | |||||
EBITDA Margin % | -17870.05 | |||||
ROA % | -184.19 | |||||
ROIC % | -126.75 | |||||
3-Year ROIIC % | -405.65 | |||||
ROC (Joel Greenblatt) % | -378.31 | |||||
ROCE % | -265.35 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 225.63 | |||||
EV-to-EBIT | -1.61 | |||||
EV-to-EBITDA | -1.68 | |||||
EV-to-Revenue | 299.78 | |||||
EV-to-FCF | -3.71 | |||||
Earnings Yield (Greenblatt) % | -62.11 | |||||
FCF Yield % | -34.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CLNNW
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Clene Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0 - 3.2 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clene Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clene Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 65 days | ||
| HC Wainwright 28(th) Annual Global Investment Conference | 2026-09-15 13:30 | In 7 days | ||
| Guidance call for 2026 | 2026-09-09 09:10 | In 1 day | ||
| Emerging Growth Conference | 2026-08-19 15:10 | -- | ||
| Second quarter earnings results for 2026 | 2026-08-14 | -- | ||
| General meeting for 2026 | 2026-05-21 11:00 | -- | ||
| First quarter earnings results for 2026 | 2026-05-14 | -- | ||
| Emerging Growth Conference | 2026-05-06 15:25 | -- | ||
| Annual report for 2025 | 2026-03-17 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | -- |
Show
Entries
Clene Inc Frequently Asked Questions
What is Clene Inc(CLNNW)'s stock price today?
The current price of CLNNW is $0.00. The 52 week high of CLNNW is $3.20 and 52 week low is $0.00.
When is next earnings date of Clene Inc(CLNNW)?
The next earnings date of Clene Inc(CLNNW) is 2026-11-13 Est..
Does Clene Inc(CLNNW) pay dividends? If so, how much?
Clene Inc(CLNNW) does not pay dividend.
Press Release
Articles on Clene Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers